Edwards Lifesciences, has been identified as the company subject to unannounced raids by the EU commission on September 19th, 2023. 

The raid was conducted as part of an investigation into abuses and breaches of EU antitrust regulations, related to Article 102 of the Treaty on the Functioning of the European Union, which prohibits abuses of a dominant market position.  

In a statement on the Edwards Lifesciences website the company said: “Edwards Lifesciences is cooperating with the European Commission regarding its inspection in relation to EU competition law. We have an unwavering commitment to healthy, fair competition; when innovative companies like ours compete, patients benefit. We remain confident in our business practices and will not be commenting further at this time.” 

The original press release from the EU commission gave minor details of the operation and did not name the target of the investigation. The statement only alluded to the company being a specialist in medical devices for cardiovascular applications. 

If found guilty of violating EU antitrust rules Edwards Lifesciences could be fined as much as 10% of its global turnover. 

Reuters were the first to break the story and reported Edwards Lifesciences’ shares dipped 2.5% in pre-market trade after the news was released.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Earlier in September, Edwards Lifesciences had the world’s first patient in a clinical trial to test its device aimed at relieving symptoms of heart failure. 

In August 2023 the firm also received 510(k) clearance for the Smart Wedge Algorithm

According to a GlobalData report, global market value for cardiovascular devices will grow at a compound annual growth rate (CAGR) of 6% to $62 billion by 2025.